Effects of Combined Granulocyte–Macrophage Colony-Stimulating Factor (GM-CSF), Interleukin-2, and Interleukin-12 based Immunotherapy against Intracranial Glioma in the Rat

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Journal of Neuro-Oncology

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1023/B:NEON.0000013477.94568.0fPMID 15015768
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cancer vaccines

  2005cited by this paper
• Granulocyte macrophage-colony stimulating factor gene transfer to induce a protective anti-tumoral immune response against the 9L rat gliosarcoma model.

  2002cited by this paper
• Local tumor irradiation augments the antitumor effect of cytokine-producing autologous cancer cell vaccines in a murine glioma model

  2002cited by this paper
• GM-CSF-based cellular vaccines: a review of the clinical experience.

  2002cited by this paper
• Complete Regression of Established Spontaneous Mammary Carcinoma and the Therapeutic Prevention of Genetically Programmed Neoplastic Transition by IL-12/Pulse IL-2: Induction of Local T Cell Infiltration, Fas/Fas Ligand Gene Expression, and Mammary Epithelial Apoptosis1 2

  2001cited by this paper
• Adoptive immunotherapy in patients with recurrent malignant glioma: preliminary results of using autologous whole-tumor vaccine plus granulocyte-macrophage colony-stimulating factor and adoptive transfer of anti-CD3-activated lymphocytes.

  2000cited by this paper
• Helper Virus-Free Herpes Simplex Virus Type 1 Amplicon Vectors for Granulocyte-Macrophage Colony-Stimulating Factor-Enhanced Vaccination Therapy for Experimental Glioma

  2000cited by this paper
• Tumor Necrosis Factor-α Expression in Ischemic Neurons

  2000cited by this paper
• Regression of orthotopic brain tumors by cytokine-assisted tumor vaccines primed in the brain

  1999cited by this paper
• Interleukin-12 as an adjuvant for cancer immunotherapy.

  1999cited by this paper
• Anti‐tumor activity of interleukin‐2‐producing tumor cells and recombinant interleukin 12 against mouse glioma cells located in the central nervous system

  1999cited by this paper
• Tumor-targeted IL-2 amplifies T cell-mediated immune response induced by gene therapy with single-chain IL-12.

  1999cited by this paper
• Effects of continuous localized infusion of granulocyte-macrophage colony-stimulating factor and inoculations of irradiated glioma cells on tumor regression.

  1999cited by this paper
• Systemic T cell adoptive immunotherapy of malignant gliomas.

  1998cited by this paper
• Antitumor activity of interleukin 12 against interleukin 2-transduced mouse glioma cells.

  1998cited by this paper
• Dendritic cells and the control of immunity

  1998cited by this paper
• Interleukin-12-based Immunotherapy against Rat 9L Glioma

  1998influential reference
• Cancer vaccines

  1998cited by this paper
• Interleukin-12-based immunotherapy against rat 9L glioma.

  1998cited by this paper
• Intracerebral versus subcutaneous immunization with allogeneic fibroblasts genetically engineered to secrete interleukin-2 in the treatment of central nervous system glioma and melanoma.

  1997cited by this paper
• Vaccination for experimental gliomas using GM-CSF-transduced glioma cells.

  1997cited by this paper
• Gene Therapy for Metastatic Brain Tumors by Vaccination with Granulocyte-Macrophage Colony-Stimulating Factor-Transduced Tumor Cells

  1997cited by this paper
• Induction of Antitumor Immunity by Intracerebrally Implanted Rat C6 Glioma Cells Genetically Engineered to Secrete Cytokines

  1997cited by this paper
• Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer.

  1997influential reference
• Immunization with granulocyte-macrophage colony-stimulating factor-transduced, but not B7-1-transduced, lymphoma cells primes idiotype-specific T cells and generates potent systemic antitumor immunity.

  1996cited by this paper
• Systemic and local paracrine cytokine therapies using transduced tumor cells are synergistic in treating intracranial tumors.

  1996cited by this paper
• Enhanced immune priming with spatial distribution of paracrine cytokine vaccines.

  1996cited by this paper
• Induction of Autologous Tumor‐Specific Cytotoxic T‐Lymphocyte Activity Against a Human Renal Carcinoma Cell Line by B7–1 (CD80) Costimulation

  1996cited by this paper
• Adoptive immunotherapy using lymphokine-activated killer (LAK) cells and interleukin-2 for recurrent malignant primary brain tumors

  1996cited by this paper
• RG-2 glioma growth attenuation and severe brain edema caused by local production of interleukin-2 and interferon-gamma.

  1995cited by this paper
• Improved long term survival after intracavitary interleukin‐2 and lymphokine‐activated killer cells for adults with recurrent malignant glioma

  1995cited by this paper
• Therapeutic strategies for cytokines.

  1995cited by this paper
• Paracrine cytokine adjuvants in cancer immunotherapy.

  1995cited by this paper
• Demonstration of a rational strategy for human prostate cancer gene therapy.

  1994cited by this paper
• Tumor necrosis factor-alpha expression in ischemic neurons.

  1994cited by this paper
• Controlled release, biodegradable cytokine depots: a new approach in cancer vaccine design.

  1993cited by this paper
• Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.

  1993cited by this paper
• Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages.

  1993cited by this paper
• Defective presentation of endogenous antigens by a murine sarcoma. Implications for the failure of an anti-tumor immune response.

  1991cited by this paper
• Modulation of T-cell function by gliomas.

  1991cited by this paper
• Rejection of transplantable AKR leukaemia cells following MHC DNA-mediated cell transformation

  1984cited by this paper
• Glioblastoma cells release interleukin 1 and factors inhibiting interleukin 2-mediated effects.

  1984cited by this paper
• Production of prostaglandin E and an interleukin-1 like factor by cultured astrocytes and C6 glioma cells.

  1982cited by this paper
• Mechanisms of syngeneic tumor rejection. Susceptibility of host- selected progressor variants to various immunological effector cells

  1982cited by this paper
• Cell subpopulations dispersed from solid tumours and separated by centrifugal elutriation.

  1981cited by this paper
• Cellular and Humoral Aspects of the Hypersensitive States

  1959cited by this paper

• Genetically engineered macrophages persist in solid tumors and locally deliver therapeutic proteins to activate immune responses

  2020cites this paper
• Utilizing Salmonella to treat solid malignancies

  2017cites this paper
• Preclinical Immunotherapeutic Animal Models for Brain Tumors

  2017cites this paper
• Immune and viral therapies for malignant primary brain tumors

  2017cites this paper
• Overcoming the resistance of pancreatic cancer to immune checkpoint inhibitors

  2017cites this paper
• Improved Therapeutic Efficacy of Cancer Gene Therapy using RRVs Designed for Multiple

  2015cites this paper
• The Differentiation of CD4+ T-Helper Cell Subsets in the Context of Helminth Parasite Infection

  2014cites this paper
• Combined chemotherapy and immunotherapy against experimental malignant brain tumors

  2013cites this paper
• A novel subset of helper T cells promotes immune responses by secreting GM-CSF

  2013cites this paper
• Gene Therapy-Mediated Reprogramming Tumor Infiltrating T Cells Using IL-2 and Inhibiting NF-κB Signaling Improves the Efficacy of Immunotherapy in a Brain Cancer Model

  2012cites this paper
• Monocyte galactose/N-acetylgalactosamine-specific C-type lectin receptor stimulant immunotherapy of an experimental glioma. Part II: combination with external radiation improves survival

  2012cites this paper
• Granulocyte-macrophage colony-stimulating factor as an autocrine survival-growth factor in human gliomas.

  2012cites this paper
• Therapeutic brain cancer targeting by gene therapy and immunomodulation

  2012cites this paper
• Genetic and Immunology of Brain Tumors

  2011cites this paper
• Adenovirus mediated transfer of p53, GM-CSF and B7-1 suppresses growth and enhances immunogenicity of glioma cells

  2010cites this paper
• Overview of Cellular Immunotherapy for Patients with Glioblastoma

  2010cites this paper
• Autologous tumor cell vaccination plus infusion of GM-CSF by a programmable pump in the treatment of recurrent malignant gliomas.

  2010cites this paper
• Human glioma cell culture: two FCS-free media could be recommended for clinical use in immunotherapy

  2009cites this paper
• Stat3 Oncogenic Signaling in Glioblastoma Multiforme

  2009cites this paper
• The effects of systemic and intratumoral interleukin-12 treatment in C6 rat glioma model

  2008cites this paper
• Immunotherapy against malignant brain tumors - of mice and men

  2008cites this paper
• Synergism between GM–CSF and IFNγ: Enhanced immunotherapy in mice with glioma

  2007cites this paper
• Idiotype protein vaccination in combination with adjuvant cytokines in patients with multiple myeloma--evaluation of T-cell responses by different read-out systems.

  2007cites this paper
• Immunotherapy of cancer by IL-12-based cytokine combinations

  2007cites this paper
• Efficacy of an osmotic pump delivered, GM-CSF-based tumor vaccine in the treatment of upper aerodigestive squamous cell carcinoma in rats

  2007cites this paper
• Effects of syngeneic cellular vaccinations alone or in combination with GM-CSF on the weakly immunogenic F98 glioma model

  2006influential citation
• Effects of irradiated tumor vaccine and infusion of granulocyte-macrophage colony-stimulating factor and interleukin-12 on established gliomas in rats

  2006influential citation
• Enhancement of anti-tumor immunity specific to murine glioma by vaccination with tumor cell lysate-pulsed dendritic cells engineered to produce interleukin-12

  2006cites this paper
• Immunotherapy for brain tumors: quo vadis?

  2006cites this paper
• Aberrant Stat 3 Signaling by Interleukin-4 in Malignant Glioma Cells : Involvement of IL-13 R a 2

  2005cites this paper
• Aberrant Stat3 signaling by interleukin-4 in malignant glioma cells: involvement of IL-13Ralpha2.

  2005cites this paper
• Cytotoxicity of rat marrow stromal cells against malignant glioma cells

  2005cites this paper
• Immunotherapy for malignant glioma: current approaches and future directions

  2005cites this paper
• Cytokine Expression and Signaling in Brain Tumors

  2005cites this paper
• Immune Cell Subsets Direct or Antagonize Tumor Immunity: Promotion of TH1 Responses in Tumor Vaccination

  2005cites this paper
• Suppression of morphine withdrawal syndrome by interleukin-2 and its gene

  2005cites this paper